Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855915 | 1.00 | GSK3B (0.62) | GSK3BMAPK14CAMK2DIDH1MCL1 | |
| SCHEMBL5658190 | 0.91 | GSK3B (0.62) | GSK3BMAPK14CAMK2DMCL1 | |
| SCHEMBL5658993 | 0.87 | GSK3B (0.73) | GSK3BMAPK14CAMK2DIDH1MCL1 | |
| SCHEMBL4848243 | 0.85 | CAMK2D (0.47) | MAPK14CAMK2DIDH1 | |
| SCHEMBL4848233 | 0.85 | CAMK2D (0.47) | MAPK14CAMK2DIDH1 | |
| SCHEMBL4847382 | 0.84 | GSK3B (0.49) | GSK3BMAPK14CAMK2DIDH1 | |
| SCHEMBL4847379 | 0.84 | GSK3B (0.49) | GSK3BMAPK14CAMK2DIDH1 | |
| SCHEMBL13987027 | 0.76 | GSK3B (1.00) | GSK3B | |
| SCHEMBL4857179 | 0.76 | GSK3B (0.65) | GSK3B | |
| SCHEMBL5656460 | 0.74 | GSK3B (0.85) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | GSK3B 3708/4885MAPK14 3554/4885CAMK2D 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.